CYTOSINE ARABINOSIDE (Ara-C) is a pyrimidine analogue of deoxycytidine (CdR) that produces a marked inhibition of DNA synthesis in replicating cells. Ara-C is converted intracellularly to the triphosphate (Ara-CTP) which is a DNApolymerase inhibitor that competes with the normal precursor deoxycytidine triphosphate (dCTP).
Ara-C is one of the most effective drugs for the chemotherapy of acute myelogenous leukaemia (AML) but response to treatment varies. The patient's clinical condition and haematological status, together with the [3H]-TdR labelling index (LI), may account for some of this variation (Freireich et al., 1975) . Individual differences of some prognostic value are found in the pharmacokinetics of Ara-C (Ho & Frei, 1971) in the rate of its phosphorylation to Ara-CTP (Kessel et al., 1969) and in the rates of deamination of Ara-C and its monophosphate (Ara-CMP) (Steuart & Burke, 1971; Tattersall et al., 1974) .
Although intracellular concentrations of Ara-CTP might be predicted from a complete knowledge of the details of Ara-C metabolism, the extent of inhibition of DNA synthesis at any particular Ara-CTP level may also vary between different types of cell (Chou et al., 1977) . We have therefore compared the uptake of [3H]-I To whlom correspon(lence should be ad(dressed. Accepted 9 January 1980 TdR in vitro, as a measure of DNA synthesis, by normal and AML cells in order to detect any differences in their sensitivity to Ara-C.
Patients with AML were studied at diagnosis (new AML, 14) in remission (5) or in relapse (5) and had received no chemotherapy for at least 3 weeks. Marrow aspirates were passed through 26-gauge needles into tubes containing 3 ml medium (Eagle's MEM with Hanks' salts; Flow, U.K.), 1 ml dextran 110 (6% in 0.900 saline) and 200 u preservativefree heparin, and were allowed to settle at room temperature. After 15-30 min the supernatant was centrifuged at 500 revs/ min for 5 min; the cells were resuspended in fresh medium and passed through a stainless-steel mesh (36dm apertures). Normal marrow was obtained from ribs taken from patients with non-invasive carcinoma of the bronchus or with cardiac conditions.
Between (0.45 ,um) , washed with 5% TCA followed by propan-2-ol. Filters were dissolved in 0 3 ml acetone and the released precipitate was suspended in 11b5 ml Aquasol (New England Nuclear, Dreiechenhain, W. Germany) and gelled with 3-5 ml water. Samples were counted for 100 min or to 40,000 counts. Channel-ratio quench correction was used, and efficiencies ranged from 14 to 22%.
Cells from parallel incubations without Ara-C were washed and fixed with 3 parts methanol to 1 part glacial acetic acid. Slides were made by an air-drying technique and stained with aceto-orcein. Autoradiographs were prepared using ARIO stripping film (Kodak) and exposed at 4°C for 5 days. After processing, the LI was determined as the percentage of cells labelled ( > 5 grains) from samples of 1000 cells.
[3H]-TdR uptake at each point on the dose-response curves were compared between patient groups, using Student's t test. Further statistical comparisons were facilitated by fitting cubic curves to each set of data, using a least-squares method. Variances were stabilized by conversion of uptake data to log 00 of controls, and goodness of fit was determined by analysis of variance. Poor fit was generally due to distortion by terminal values on the plateau portions of the curve. Removal of one or two sets of values without encroaching on the sloped portions of the curves allowed good fit to be obtained. Cubic curves were considered particularly suitable for the present data, as some doseresponse curves showed reversal at the highest and lowest Ara-C concentrations.
No significant differences were found between the percentage [3H]-TdR uptake of normal and remission marrows at each Ara-C concentration (Fig. 1) Calculated inhibition values for Ara-C concentrations between 10 nm and 100 /M were compared between patient groups. Rib and remission data were now indistinguishable, as were new AML and relapse marrow data. Comparison of the 16 pooled normal and pooled AML groups showed a greater inhibition of AML at 10 nM and 100 nM (both 0 01 >P>0 005) whilst at 100 ,iM normal marrow was more inhibited (0 05 >P> 002). Variances at 10 nm and 100 VM were significanttly greater in AML than in normal marrow data (0.02 >P > 0 002).
Normal and remission marrows had a similar LI (pooled mean 11.2%, s.d. 2.9%). The LI of pooled AML marrow (mean 8 2 %) was not significantly different from normal marrow, although the variation was greater (s.d. 7.2%, range 1.0-32*6%). The LI in each group of marrows was not significantly correlated with the inhibition of [3H]-TdR uptake at any part of the Ara-C dose-response curves.
Inhibition of [3H]-TdR (and 3H-deoxyuridine) uptake by normal and leukaemic cells incubated for 4 h with Ara-C has been previously described (Wilmanns, 1971) but full dose-response curves were not obtained in the few patients studied. In another study leukaemic cells were preincubated with 4 Hm Ara-C before addition of [14C]-TdR or 3H-uridine, and inhibition was positively correlated with prognosis for remission (Zittoun et al., 1975) .
In the present study, AML cells were on average more sensitive to Ara-C at low concentrations and exhibited greater variation than normal marrow, although there was some overlap in sensitivity. The rates of cellular deamination and phosphorylation of Ara-C and its derivatives differ between patients with AML (Chabner et al., 1974; Coleman et al., 1975) . They also vary with the stage of treatment (Chou et al., 1977) and have some correlation with subsequent attainment of remission (Steuart & Burke, 1971; Tattersall et al., 1974 (Ho & Frei, 1971) . AML cells differ widely in their cellkinetic parameters (Skipper & Perry, 1970) , and this might be related to the sensitivity to Ara-C. However, there was no correlation between the LI or the absolute uptake of [3H]-TdR in controls and the sensitivity of any group to Ara-C.
Our experiments were performed with cells incubated for 30 min with fixed concentrations of Ara-C, which is analogous to the administration of short infusions in vivo. The patients were treated with intermittent boluses of Ara-C together with daunorubicin, so it is not surprising that cell sensitivity to Ara-C was not correlated with subsequent remission. It is possible that the observed in vitro differential effect of 10-100 nM Ara-C might be evident in patients given Ara-C in the form of continuous low-dose infusions. Our preliminary experience with such infusions, at doses based on the individual's clearance of Ara-C and the in vitro sensitivity of their cells, has been encouraging and clinical studies are in progress.
